CannGros
CannGros ApS is a Danish pharmaceutical supplier of five standardized medical cannabis flower products (Bedrocan, Bedica, Bedrolite, Bediol, Bedrobinol) approved by the Danish Medicines Agency and dispensed via Danish pharmacies on prescription. Acquired by STENOCARE A/S in November 2025.
- Company typePrivate
- Founded2017
- HeadquartersRye, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What CannGros does
CannGros ApS is a Danish supplier of medical cannabis products, founded in 2017 and headquartered in Rye, Denmark. The company specializes in importing cannabis raw materials and manufacturing standardized dried cannabis flower products under Denmark's permanent medical cannabis law. CannGros holds approvals from the Danish Medicines Agency (Lægemiddelstyrelsen) for five flower products covering the therapeutic spectrum: Bedrocan (220 mg/g THC), Bedica (140 mg/g THC), Bedrobinol (135 mg/g THC), Bediol (63 mg/g THC and 80 mg/g CBD balanced), and Bedrolite (75 mg/g CBD). Products are manufactured under controlled cultivation conditions without pesticides, tested for heavy metals and impurities, and standardized to fixed cannabinoid concentrations across batches. Each box includes an approved graduated measuring spoon (0.5ml–10ml) to enable accurate patient dosing.
CannGros operates a B2B2C pharmaceutical distribution model: products move through established Danish pharmaceutical wholesalers to all Danish pharmacies, where they are dispensed to patients holding valid prescriptions. End customers are Danish patients with chronic pain, multiple sclerosis, spinal cord injury, or chemotherapy-induced nausea; any authorized Danish physician may prescribe at their discretion. Pricing is governed by a national subsidy scheme providing 50% reimbursement up to DKK 20,000 of annual expenditure (maximum DKK 10,000 subsidy per year) and 100% reimbursement for terminal patients, with subsidies deducted automatically at the pharmacy.
In November 2025, STENOCARE A/S acquired 100% of CannGros from DanCann Pharma A/S via a 7.4 mDKK share-for-share exchange (5 million new STENOCARE shares issued). CannGros now operates as a STENOCARE brand ("CannGross – a STENOCARE brand"), and STENOCARE subsequently raised flower prices by approximately 45%. The acquisition is expected to contribute DKK 4–6 million in annual revenue from 2026 and consolidates STENOCARE's dominant position in the Danish medical cannabis market across both flower and oil categories.
CannGros firmographics
Firmographics- Name
- CannGros
- Legal name
- CannGros ApS
- Website
- https://canngros.dk
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- CannGros ApS is a Danish pharmaceutical supplier of five standardized medical cannabis flower products (Bedrocan, Bedica, Bedrolite, Bediol, Bedrobinol) approved by the Danish Medicines Agency and dispensed via Danish pharmacies on prescription. Acquired by STENOCARE A/S in November 2025.
- Ownership category
- akta.pro rank
CannGros industry classification
Industry- Product category
- Medical Cannabis Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Medical Cannabis Dispensaries (CRANAFAB)
- akta.pro secondary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where CannGros is headquartered
LocationHeadquarters
- HQ city
- Rye
- HQ country
- Denmark
- HQ region
- Europe
Markets served
CannGros business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: CannGros generates revenue through the sale of approved medical cannabis products to patients via pharmacies. Products are distributed through established pharmaceutical wholesalers. Revenue flows from pharmacies purchasing products, which are dispensed to patients with valid prescriptions. The acquisition by STENOCARE contributed an estimated DKK 4–6 million in annual revenue from 2026 onwards.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Danish government subsidy scheme for medical cannabis |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
CannGros product offering
Product offeringCore offering
CannGros ApS is an approved Danish pharmaceutical supplier of medical cannabis flower products under Denmark's permanent medical cannabis law. The company manufactures and supplies five standardized dried cannabis flower products (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) with fixed levels of active compounds dronabinol (THC) and CBD, distributed through pharmaceutical wholesalers to Danish pharmacies for dispensing to patients via prescription.
Product overview
CannGros ApS is a Danish supplier of medical cannabis products approved under Denmark's permanent medical cannabis law. The company offers a portfolio of five standardized dried cannabis flower products: Bedrocan (whole flowers, high THC), Bediol (crushed flowers, balanced THC/CBD), Bedica (crushed flowers, high THC), Bedrolite (crushed flowers, high CBD), and Bedrobinol (whole flowers, high THC). All products contain standardized levels of active compounds dronabinol (THC) and CBD, and are available through Danish pharmacies via prescription. CannGros was acquired by STENOCARE A/S in November 2025.
Differentiator
Problem solved
Functional benefit
Products and services
- Bedrocan CannGros Whole dried cannabis flowers of the Cannabis Sativa L. 'Afina' strain containing 220 mg/g THC and less than 10 mg/g CBD, approved under Denmark's medical cannabis trial scheme for dispensing via prescription.
- Bediol CannGros Crushed dried cannabis flowers of the Cannabis Sativa L. 'Elida' strain containing 63 mg/g THC and 80 mg/g CBD, providing a balanced THC/CBD formulation approved under Denmark's medical cannabis trial scheme.
- Bedica CannGros Crushed dried cannabis flowers of the Cannabis Sativa L. 'Talea' strain containing 140 mg/g THC and less than 10 mg/g CBD, approved under Denmark's medical cannabis trial scheme for THC-dominant therapy.
- Bedrolite CannGros Crushed dried cannabis flowers of the Cannabis Sativa L. 'Rensina' strain containing 75 mg/g CBD and less than 10 mg/g THC, providing a CBD-dominant formulation approved in 2025 under Denmark's medical cannabis trial scheme.
- Bedrobinol CannGros Whole dried cannabis flowers of the Cannabis Sativa L. 'Ludina' strain containing 135 mg/g THC and less than 10 mg/g CBD, approved in 2025 under Denmark's medical cannabis trial scheme as a THC-dominant product.
Quantifiable outcome
- Post-acquisition, STENOCARE raised flower prices by approximately 45%, indicating strong pricing power in the consolidated Danish market.
Companies that use CannGros
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles2 records
CannGros technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CannGros partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- STENOCARE A/ScoreSTENOCARE A/S acquired 100% of CannGros ApS from DanCann Pharma A/S in November 2025 through a share-for-share exchange. STENOCARE issued 5 million new shares to DanCann Pharma. The acquisition added five approved cannabis flower products to STENOCARE's portfolio and was expected to contribute DKK 4–6 million in additional annual revenue from 2026. Post-acquisition, STENOCARE raised flower prices by approximately 45%, consolidating its dominant position in the Danish medical cannabis market.
Scale indicators5 records
Recent moves5 records
Expansion highlights4 records
CannGros competitors and assessment
Company assessmentBroad incumbents
- Jazz Pharmaceuticals (GW Pharmaceuticals): Owns Sativex and Epidiolex, the leading cannabinoid-based prescription medicines globally. Comparable as a broad incumbent in the medical cannabis / cannabinoid therapy space, though operating with regulator-approved medicines rather than flower products.
- Canopy Growth Corporation: Global cannabis producer with a substantial European medical cannabis business (Spectrum Therapeutics). Comparable as a broad incumbent supplying standardized cannabis flower and cannabinoid medicines to European pharmacy channels.
- Aurora Cannabis Inc. Large Canadian-licensed medical cannabis producer with European distribution operations including Germany and Denmark. Comparable as a broad incumbent supplying standardized medical cannabis flower into European pharmacy channels.
- Tilray Brands: Global medical and consumer cannabis company with a major European medical cannabis footprint, including operations in Germany and Portugal. Comparable as a broad incumbent supplying GMP-certified medical cannabis flower and extracts to pharmacies.
Regional players
- Demecar GmbH: German medical cannabis importer and distributor operating one of Germany's largest flower portfolios. Comparable as a regional peer with a similar pharmacy-channel B2B model and standardized flower product focus, though serving Germany rather than Denmark.
- Sanity Group: Berlin-based European medical cannabis company (including Sanity Medical and Vayamed brands) supplying German pharmacies. Comparable as a regional peer in the European medical cannabis flower distribution market.
- Cannamedical Pharma GmbH: German medical cannabis wholesaler distributing a wide portfolio of flower and extracts to German pharmacies. Comparable as a regional peer with a similar B2B pharmacy distribution model and standardized cannabis flower offering.
Direct peers
- Bedrocan International: Dutch licensed producer of standardized medicinal cannabis flowers and the upstream cultivar supplier for CannGros's Bedrocan, Bedica, Bediol, Bedrolite, and Bedrobinol brands. Operates in adjacent European medical cannabis markets with similar GMP-grade flower products.
- DanCann Pharma A/S: Former parent of CannGros and Danish medical cannabis operator focused on imported flower products. Operates in the same regulatory framework under Denmark's medical cannabis law and previously distributed CannGros's portfolio.
- STENOCARE A/S: Danish Nasdaq First North-listed medical cannabis company that acquired CannGros in November 2025. Operates the same Danish pharmacy distribution channel and offers complementary cannabis oil products, making it the closest direct peer and now parent company.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
CannGros compliance and trust
Trust signalCompliance1 record
CannGros financial estimates
Financial estimateRevenue estimate
Valuation estimate
CannGros leadership team
Management profileNumber of profiles
CannGros funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CannGros M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CannGros
What does CannGros do?
CannGros ApS is an approved Danish pharmaceutical supplier of medical cannabis flower products under Denmark's permanent medical cannabis law. The company manufactures and supplies five standardized dried cannabis flower products (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) with fixed levels of active compounds dronabinol (THC) and CBD, distributed through pharmaceutical wholesalers to Danish pharmacies for dispensing to patients via prescription.
Is CannGros a public or private company?
CannGros is a private company. It is classified as corporate owned and is currently acquired.
When was CannGros founded?
CannGros was founded in 2017. It employs 1 to 10 people.
Where is CannGros based?
CannGros is headquartered in Rye, Denmark, in the Europe region.
How does CannGros make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are CannGros's main competitors?
Broad incumbents on record are Jazz Pharmaceuticals (GW Pharmaceuticals), Canopy Growth Corporation, Aurora Cannabis Inc. and Tilray Brands. Regional players are Demecar GmbH, Sanity Group and Cannamedical Pharma GmbH. Direct peers are Bedrocan International, DanCann Pharma A/S and STENOCARE A/S.
Does CannGros have an API?
No public API is recorded for CannGros.
What industry is CannGros in?
CannGros's product category is Medical Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325411 and its SIC code is 2833.